Incidence of musculoskeletal and neoplastic diseases in patients on statin therapy: Results of a retrospective cohort analysis

American Journal of the Medical Sciences

Volumn 345, Issue 5, 2013, Pages 343-348

  Mansi, Ishak A ^a   Mortensen, Eric M ^b   Pugh, Mary J ^c   Wegner, Michael ^d   Frei, Christopher R ^a,e  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d BROOKE ARMY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Arthropathy; Musculoskeletal; Neoplasm; Side effects; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTHROPATHY; ARTICLE; CHARLSON COMORBIDITY INDEX; CHONDROPATHY; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEOPLASM; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PRESCRIPTION; RETROSPECTIVE STUDY; RHEUMATIC DISEASE;

EID: 84876871524     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31825b8edf     Document Type: Article

References (50)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
2. Robinson JG, Smith B, Maheshwari N, et al. Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005;46:1855-62.
3. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
4. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
5. Mason RP, Walter MF, Day CA, et al. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 2005; 96:11F-23F.
6. Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins - mechanisms and consequences. Curr Drug Saf 2009;4:209-28.
7. Goldstein MR, Mascitelli L, Pezzetta F. The double-edged sword of statin immunomodulation. Int J Cardiol 2009;135:128-30.
8. Marie I, Delafenetre H, Massy N, et al. Tendinous disorders attributed to statins: A study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. Arthritis Rheum 2008;59:367-72.
9. Carmont MR, Highland AM, Blundell CM, et al. Simultaneous bilateral Achilles tendon ruptures associated with statin medication despite regular rock climbing exercise. Phys Ther Sport 2009;10:150-2.
10. Beri A, Dwamena FC, Dwamena BA. Association between statin therapy and tendon rupture: A case-control study. J Cardiovasc Pharmacol 2009;53:401-4.
11. Pullatt RC, Gadarla MR, Karas RH, et al. Tendon rupture associated with simvastatin/ezetimibe therapy. Am J Cardiol 2007;100:152-3.
12. Alsheikh-Ali AA, Trikalinos TA, Kent DM, et al. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 2008;52: 1141-7.
13. Steinberg D. Statin treatment does not cause cancer. J Am Coll Cardiol 2008;52:1148-9.
14. Kemmler G, Hummer M, Widschwendter C, et al. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: A meta-analysis. Arch Gen Psychiatry 2005;62:1305-12.
15. Owens DK, Qaseem A, Chou R, et al. High-value, cost-conscious health care: Concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med 2011;154:174-80.
16. Steinberg D. Earlier intervention in the management of hypercholesterolemia: What are we waiting for? J Am Coll Cardiol 2010;56:627-9.
17. Forrester JS. Redefining normal low-density lipoprotein cholesterol: A strategy to unseat coronary disease as the nation's leading killer. J Am Coll Cardiol 2010;56:630-6.
18. Kugler J. Military health system patient centered medical home guide: Tricare. Office of the Chief Medical Officer, Department of Defense. 2011.
19. M2 MHSManagement Analysis and Reporting Tool Executive Information and Decision Support for the MHS. Available at: http://www.tricare. mil/mhsophsc/mhs-supportcenter/Library/1-M2.pdf. Accessed January 7, 2012.
20. Luhrman S, Lehr E, Hefflin C, et al. Interface control document describing the case management exchange from BEA to MDR and M2 baseline. Falls Church (VA): DHSS; 2008.
21. Gantt CJ, Neely JA, Villafana IA, et al. Analysis of weight and associated health consequences of the active duty staff at a major Naval medical center. Mil Med 2008;173:434-40.
22. George SZ, Childs JD, Teyhen DS, et al. Brief psychosocial education, not core stabilization, reduced incidence of low back pain: Results from the Prevention of Low Back Pain in the Military (POLM) cluster randomized trial. BMC Med 2011;9:128.
23. Enewold L, Brinton LA, McGlynn KA, et al. Oral contraceptive use among women in the military and the general U.S. population. J Womens Health (Larchmt) 2010;19:839-45.
24. Moniz C. Outpatient workload (RVU) predictors: Age, gender & beneficiary category. Baltimore (MD): U.S. Army Medical Department Center and School; 2008.
25. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
26. Buchbinder R, Goel V, Bombardier C. Lack of concordance between the ICD-9 classification of soft tissue disorders of the neck and upper limb and chart review diagnosis: One steel mill's experience. Am J Ind Med 1996;29:171-82.
27. Mausner-Fainberg K, Luboshits G, Mor A, et al. The effect of HMGCoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008;197:829-39.
28. Yu JG, Sewright K, Hubal MJ, et al. Investigation of gene expression in C(2)C(12) myotubes following simvastatin application and mechanical strain. J Atheroscler Thromb 2009;16:21-9.
29. Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51:415-26.
30. Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet 2004;363:892-4.
31. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359:1343-56.
32. Alsheikh-Ali AA, Maddukuri PV, Han H, et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials. J Am Coll Cardiol 2007;50:409-18.
33. Ben-Yehuda O, DeMaria AN. Low LDL-C levels and cancer reassuring but still not definitive. J Am Coll Cardiol 2008;52:1150-1.
34. Beck P, Wysowski DK, Downey W, et al. Statin use and the risk of breast cancer. J Clin Epidemiol 2003;56:280-5.
35. Setoguchi S, Glynn RJ, Avorn J, et al. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007; 115:27-33.
36. Marelli C, Gunnarsson C, Ross S, et al. Statins and risk of cancer: A retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol 2011;58:530-7.
37. Karp I, Behlouli H, Lelorier J, et al. Statins and cancer risk. Am J Med 2008;121:302-9.
38. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: A cautionary tale. Circulation 2009;119:2051-7.
39. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
40. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45.
41. Jacobson TA. Toward "pain-free" statin prescribing: Clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008;83: 687-700.
42. Hsia J, MacFadyen JG, Monyak J, et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol, 50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011;57:1666-75.
43. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14.
44. Fernandez G, Spatz ES, Jablecki C, et al. Statin myopathy: A common dilemma not reflected in clinical trials. Cleve Clin JMed 2011;78:393-403.
45. Jordan K, Clarke AM, Symmons DP, et al. Measuring disease prevalence: A comparison of musculoskeletal disease using four general practice consultation databases. Br J Gen Pract 2007;57:7-14.
46. Bell N, Hollander I, Williams J, et al. A tale of two disability coding systems: The Veterans Administration Schedule for Rating Disabilities (VASRD) vs. Diagnostic Coding using the International Classification of Diseases, 9th edition, clinical modification (ICD-9-CM). Natick (MA): U.S. Army Research Institute of Environmental Medicine; 2008.
47. Caplan L, Pittman CB, Zeringue AL, et al. An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy. Mayo Clin Proc 2010;85:341-8.
48. Gray D, Ward A, Underwood P, et al. Morbidity coding in general practice. Fam Pract 1989;6:92-7.
49. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
50. Food and Drug Administration. FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. http://www.fda.gov/Drugs/DrugSafety/ ucm256581.htm. Accessed June 15, 2011.